

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

STIEKEMA ET AL.

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: November 2, 2001

Examiner: To be assigned

For: USE OF OLIGOSACCHARIDE FOR PREVENTING BLOOD CLOTTING IN
EXTRACORPOREAL BLOOD CIRCUITS

Divisional of: USSN 09/424,626, filed November 24, 1999

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Assistant Commissioner of Patents
Washington, D.C. 20231

November 2, 2001

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. These references were cited in the parent application USSN 09/424,626, and thus no copies are enclosed.

No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the last of (1) issuance of a first official action on the merits and (2) expiration of the three month period following filing of the above-captioned application.


The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. It is respectfully requested that the



information be considered during the prosecution of this application and that the cited documents be listed on the front page of any patent issuing from this application.

The Patent Office is authorized to charge our Deposit Account No. 02-2334 for any fee which it deems to be required to effect consideration of this statement.

Respectfully submitted,


William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Attorney Docket No. O/97277 US/D1
Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

WMB:lcf
111STIEKEMA-DIVIDS